Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Phase 3 Study of RPC1063 in Relapsing MS
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Daclizumab Therapy for Multiple Sclerosis.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
BTG plc Close Period Update
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063

Pages